ADCS BENFO-TEAM
- The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer’s disease.
Inclusion Criteria:
- 50 years to 89 years
- Mild Cognitive Impairment or Alzheimer’s Disease
- Availability of a designated study partner (full criteria in link below)
What to Expect
- Participants will receive either a low dose or high dose of benfotiamine or a placebo as an oral medication. A placebo looks like the study drug but contains no real medicine
- For more information click the link above or contact Tiffany Hoefler at thoefler@dentinstitute.com or 716-961-9219
Subscribe To Our Newsletter
Sign up to receive email updates on announcements, new services added, company updates & more!
Want to participate in a study?
Fill out the form below and one of our Research Coordinators will be in contact with you as soon as possible. If we currently do not have a study that is currently available for you, we will add you to our database for future studies.